Insider · CIK 0001766525
Michael D. Walkenhorst
Files at VRTV (Veritiv Corp). First filing -, latest -.
In brief
Michael D. Walkenhorst files SEC Form 4 as officer at VRTV (Veritiv Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michael D. Walkenhorst has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 30, 2023 | VRTV Veritiv Corp | DDisposition to issuer Common Stock | -2,616 | $170.00 | $445k | 0 | Nov 30, 2023 |
| Nov 30, 2023 | VRTV Veritiv Corp | DDisposition to issuer Common Stock | -9,314 | $170.00 | $1.6M | 0 | Nov 30, 2023 |
| Nov 30, 2023 | VRTV Veritiv Corp | DDisposition to issuer Performance Share Unitsderivative | -4,214 | $170.00 | $716k | 0 | Nov 30, 2023 |
| Nov 27, 2023 | VRTV Veritiv Corp | GGift Common Stock | -5,883 | $0.00 | $0 | 11,930 | Nov 28, 2023 |
Questions about Michael D. Walkenhorst
Answered from the filings on this page, as of the latest one.
Is Michael D. Walkenhorst buying or selling?
Michael D. Walkenhorst has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michael D. Walkenhorst's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael D. Walkenhorst has 0.
Where does Michael D. Walkenhorst file Form 4?
Michael D. Walkenhorst has filed Form 4 at VRTV (Veritiv Corp) as SVP Pkg. and Global Operations. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.